Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Diffusion Pharmaceuticals Shares Move Higher; Zacks Small-Cap Research Sets $2 Valuation

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03232022_DFFN_Bautz.pdf

byBenzinga Newsdesk

March 23, 2022

1 minute read

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_03232022_DFFN_Bautz.pdf

Citigroup Initiates Coverage On AES with Buy Rating, Announces Price Target of $27

By Benzinga Newsdesk

Today, 3:46 PM

Citigroup analyst Ryan Levine initiates coverage on AES (NYSE:AES) with a Buy rating and announces Price Target of $27.

AES

Keybanc Maintains Overweight on Five9, Raises Price Target to $94

By Benzinga Newsdesk

Today, 3:46 PM

Keybanc analyst Thomas Blakey maintains Five9 (NASDAQ:FIVN) with a Overweight and raises the price target from $86 to $94.

FIVN

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Raises Price Target to $19

By Benzinga Newsdesk

Today, 3:46 PM

HC Wainwright & Co. analyst Vernon Bernardino maintains Aridis Pharmaceuticals (NASDAQ:ARDS) with a Buy and raises the price target from $11 to $19.

ARDS

Is Microsoft Gearing Up For A Big Move?

By Tyler Bundy

Today, 3:46 PM

Microsoft Corporation (NASDAQ: MSFT) shares are trading slightly lower Thursday, although Jefferies analyst Brent Thill raised the price target on the stock to $400 from $375 and kept a Buy rating on the shares. This price target implies a 26.7% upside.

MSFT

Diffusion Pharmaceuticals Shares Move Higher; Zacks Small-Cap Research Sets $2 Valuation

Related Posts

Citigroup Initiates Coverage On AES with Buy Rating, Announces Price Target of $27

Keybanc Maintains Overweight on Five9, Raises Price Target to $94

HC Wainwright & Co. Maintains Buy on Aridis Pharmaceuticals, Raises Price Target to $19

Is Microsoft Gearing Up For A Big Move?